Manuscript Title: The Real-World Clinical Benefits of GLP-1 Receptor Agonist Treatment

Author List:

Henriette Coetzer, MD[1]

Caroline Margiotta, MA[1]

Amy Marr, PhD[1]

Razia Hashmi, MD[2]

Jason Kay, PharmD[2]

Vikrant Vats, PhD[2]

Stuart Hagen, PhD[2]

Stephanie Tomlin, MS[1]

Laura Anatale-Tardiff, MPH[1]

David Wennberg, MD[1]

Affiliations: 1) Blue Health Intelligence, Chicago, IL; 2) Blue Cross Blue Shield

Association, Chicago, IL

Corresponding Author: Henriette Coetzer, MD, Blue Health Intelligence, 200 E

Randolph St, Suite 3050, Chicago, IL 60601

henriette.coetzer@bluehealthintelligence.com

Manuscript word count: 2597, excluding abstract, acknowledgements, and

references

Abstract

Background: The cardiovascular, metabolic and renal benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been established in randomized trials with carefully selected patients. Real-world evidence of GLP-1RA effects on progression to end-stage renal disease (ESRD), end-stage liver disease (ESLD), and major adverse cardiovascular events (MACE) is scant.

Methods: We conducted a large retrospective cohort study of GLP1-RA use in adults using a national medical and pharmacy claims dataset. GLP-1RA users were stratified by diabetes status and propensity score-matched to controls. Outcomes were incident ESRD, ESLD, MACE overall and by treatment persistence (<1 year, 1–<2 years, ≥2 years). Cox models were used to estimate adjusted hazard ratios (HRs) and to calculate confidence intervals (CIs).

Results: In members with diabetes, GLP-1RA therapy was associated with reduced risks of ESRD (HR, 0.55; 95% CI, 0.49 to 0.61), ESLD (HR=0.66; 95% CI 0.60-0.73) and MACE (HR=0.90; 95% CI 0.86-0.93). In members without diabetes, while the incidence rates of adverse outcomes were lower, treatment with GLP-1RAs still resulted in lower risk of ESRD (HR=0.66, CI 0.46-0.94), ESLD (HR-0.76, CI 0.62-0.93) and MACE (HR=0.86, CI 92-0.99). Persistent GLP-1RA treatment (≥2 years) in members with diabetes resulted in the largest observed reduction in ESRD, ESLD, and MACE risk.

Conclusions: GLP-1RA treatment was associated with reduced incidence of kidney and liver failure and MACE. The impact of GLP-1RA treatment was greatest in members with diabetes and those persisting for ≥2 years.

Introduction

Obesity and type-2 diabetes (T2DM) continue to drive rising morbidity, mortality, and healthcare costs in the United States.[1-6] Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for glycemic control in T2DM, have emerged as transformative therapeutics for multiple indications. [7-11] Randomized controlled trials (RCTs) including LEADER, SUSTAIN-6, and REWIND demonstrated GLP-1RA efficacy in reducing major adverse cardiovascular events (MACE), improving renal outcomes, and contributing to weight loss in patients with and without diabetes.[12] These findings have rapidly expanded the clinical indications and utilization of GLP-1RA therapies.

Preclinical and translational studies find GLP-1RAs exert anti-inflammatory effects, enhance natriuresis and reduce oxidative stress, which improves endothelial function. These mechanisms appear to preferentially benefit microvasculature of the kidneys and brain, with less immediate impact on macrovascular territories such as coronary arteries.[13-17] However, GLP-1RA clinical trials have consistently underrepresented older adults, individuals with advanced chronic kidney disease (CKD), and those with multiple chronic conditions - populations common in real world practice who may experience different risks, adherence challenges, and therapeutic benefits.

We evaluated the real-world association between GLP-1RA treatment and the incidence and timing of end-stage renal disease (ESRD), end-stage liver disease (ESLD), and MACE using a large national claims database in members with and without diabetes. Leveraging real-world data, we aim to extend the understanding of GLP-1RA therapeutic effects beyond the constraints of clinical trial populations—to inform clinical care, risk stratification and value-based risk sharing arrangements. Our

71 primary hypothesis is that sustained GLP-1RA use reduces the cumulative incidence

72 of ESRD, ESLD and MACE and delays their onset.

73 **Methods**

74 **Ethics statement**

75   This study was deemed exempt by the Sterling Institutional Review Board

76 (protocol #12167) with waiver of informed consent and followed the Strengthening

77 the Reporting of Observational Studies in Epidemiology (STROBE) reporting

78 guidelines.

79 **Setting and Data Sources**

80   We used the Blue Cross Blue Shield (BCBS) Association's National Data

Warehouse,[1] containing medical claims data from participating BCBS plans. Adults

aged 18-64 (January 1, 2016-August 31, 2024) residing in the United States with

commercial medical and pharmacy insurance were potentially eligible

(N=24,987,055; Table S1).

Cohort Construction

<u>Treated members</u> had ≥1 pharmacy claims for a GLP-1RA product (tirzepatide,

albiglutide, semaglutide, liraglutide, lixisenatide, dulaglutide, or exenatide) between

January 1, 2017 and February 29, 2024, with ≥12 months baseline continuous medical

and pharmacy enrollment and ≥6 months follow-up after the initial prescription fill

(index date; N=1,725,097).

<u>Control members</u> had no prescription fills for any GLP-1RA products between

January 1, 2017 and August 31, 2024 and ≥18 months of continuous medical and

---

[1] The National Data Warehouse (NDW) is a national data asset managed by BCBSA that houses BCBS Plan submitted data (e.g., medical claims, membership data) to support healthcare operations, program capabilities, and analytics.

pharmacy enrollment (N=23,261,958). Controls were randomly assigned a proxy

exposure or pseudo-index date within quarterly periods from January 1, 2017 through

February 29, 2024.[18]

Members in both cohorts were classified as having a condition if they had ≥1 inpatient

facility claims or ≥2 professional claims on separate days (excluding ambulance,

DME, laboratory, and imaging claims) with relevant ICD-10 diagnoses in their

baseline year. Both cohorts excluded members with GLP-1RA contraindications,

high-cost conditions (e.g. cancers except squamous and basal cell carcinoma,

mechanical ventilation > 96 hours), conditions limiting long-term treatment (e.g.

dementia, end of life conditions), or bariatric procedures, yielding 936,777 treated

members and 18,281,409 eligible controls (Table S1).

Matching

Treated members were exact-matched to controls on gender, age group, index

or pseudo-index year-quarter, and baseline diabetes and weight status. Propensity

score matching (caliper=0.05 standard deviations of the logit) was then performed on

baseline comorbidities (anxiety, depression, asthma, COPD, obstructive sleep apnea,

hypertension, dyslipidemia, cerebrovascular disease, chronic kidney disease, coronary

artery disease, heart failure (HF), early-stage liver disease, late-stage liver disease,

alcohol or opiate use disorder, pancreatitis, psoriatic and rheumatic disease, and

weight-bearing joint pain), race and ethnicity (RAND Bayesian Improved First Name

Surname Geocoding imputation), and healthcare utilization (diabetes medications,

cardiovascular medications, non-bariatric inpatient stays, and number of unique drug

classes filled).[19] A 1:1 match ratio without replacement yielded 742,824 matched

pairs—413,404 with diabetes and 329,420 without diabetes. Additional information

on the definition of baseline matching conditions appears in the Methodology

Supplement.

Clinical Outcomes

Clinical outcomes were identified using a combination of International

Classification of Diseases, 10th Revision diagnosis (ICD-10-CM) codes, Current

Procedural Terminology (CPT) and Healthcare Common Procedure Coding System

(HCPCS) codes, Diagnosis-Related Groups (DRGs), and revenue center codes.

Claims for diagnostic testing, imaging, durable medical equipment, or ambulance

transport were excluded. The outcome onset date was defined as the earliest claim

date meeting the outcome criteria within the 6-year follow-up period. Outcomes

required ≥1 inpatient claim or ≥2 non-inpatient claims within 365 days except as

noted for kidney dialysis and specified MACE components.

ESRD was identified by the earliest of kidney dialysis lasting ≥28 days or a

kidney transplant.[20,21] ESLD was identified by the earliest of hepatic failure, liver

transplant, or hepatocellular carcinoma. MACE comprised: (1) ≥1 inpatient claim for

HF, acute coronary syndrome (ACS) / unstable angina (UA), acute MI, stroke, or

urgent/emergent coronary revascularization; or (2) ≥2 non-inpatient claims for acute

MI or stroke.[22]

Outcomes were censored at the earliest of the end of follow-up, the first event,

or 6 years post-index. To avoid misclassification of prevalent conditions, members

with evidence of each outcome during the 12-month baseline or within 30 days after

the index or pseudo-index date were excluded from analyses of that outcome.

Follow-Up

Members were followed until disenrollment from medical or pharmacy

benefits, the end of the study period (31 August 2024), or 6 years post-index or

pseudo-index date. Median follow-up time was 20 months for treated members and 19

months for controls. Persistence of GLP-1RA treatment was assessed by aggregating

all GLP-1RA treatment periods for each member, allowing gaps of up to 90 days;

gaps exceeding 90 days indicated discontinuation. Persistence patterns differed by

diabetes status: 52.4% of those with diabetes and 66.5% of those without diabetes

persisted for <1 year (short-term users), 29.1% of those with diabetes and 27.5% of

those without diabetes persisted for 1 to <2 years (moderate-term users), and 18.5% of

those with diabetes and 6.0% of those without diabetes persisted for ≥2 years (long-

term users; Table S3).

Statistical Analysis

Analyses were conducted with R Studio Version 2024.04.2 using the matchit

and survival packages. Baseline characteristics were summarized using means and

95% confidence intervals for continuous variables, and frequency distributions for

categorical variables.

Cox proportional hazards models estimated hazard ratios (HRs) with 95%

confidence intervals over the 6-year follow-up period, stratified by diabetes status.

Kaplan-Meier survival models assessed time-to-event outcomes, with cumulative

incidence (events per 100 person-months) estimates calculated as 1 minus the Kaplan-

Meier survival estimator, assuming no competing risks. Log-rank tests compared

survival differences between groups over the 6-year follow-up period. Proportional

hazards assumptions for the Cox models were verified using scaled Schoenfeld

residuals, where global and cohort-specific tests with non-significant p-values

confirmed proportionality. Bonferroni adjustment addressed multiple comparisons for

each outcome, where unadjusted p-values were compared to an adjusted threshold of

0.05 divided by the number of comparisons being made.

Results

Baseline characteristics

Matched treated and control members were well-balanced on demographic

and clinical characteristics. In members with diabetes, the mean age was 52.4 years in

the treated group and 52.5 years in the control group; 51.0% of each group were male

(Table 1). Most had type 2 diabetes without complications (63.7%), and the most

common comorbidities were hypertension (61.8% of treated vs 63.6% of controls)

and dyslipidemia (72.0% of treated vs 73.4% of controls). Follow-up time varied by

GLP-1RA treatment persistence. At least 3 years of follow-up were available for

34,188 short-term treated (<1 year), 11,280 medium-term treated (1 to <2 years),

41,284 long-term treated (≥2 years), and 72,805 matched controls (Table S4).

Treated and control members without diabetes had a mean age of 46.7 years,

and 75.7% were female, 45.1% had a diagnosis of obesity or overweight.

Hypertension and dyslipidemia were the most common comorbidities, with similar

prevalence between treated and control groups. At least 3 years of follow-up were

available for 20,589 short-term treated, 5,252 moderate-term treated, 7,453 long-term

treated, and 31,547 matched controls.

End-Stage Renal Disease

Treated members with diabetes had a 45% lower risk of ESRD (p<0.001)

compared to controls (Figure 1). The magnitude of the effect was similar for dialysis

and kidney transplant, the two components of ESRD (Figure 1; Table 2). We found a

strong 'persistence response curve' for ESRD in members with diabetes: those treated

for ≥2 years had a 73% lower risk (p<0.001), members treated for 1-<2 years had a

55% lower risk (p<0.001) than controls, while members treated for <1 year had no

significant risk reduction (Figure 2; Table 2). GLP-1RA treatment delayed the onset

of ESRD: at 3 years, 0.42% of controls developed ESRD, an incidence rate delayed

by 1.2 years in members with any GLP-1RA treatment and 2.7 years in members

treated for ≥2 years.

In members without diabetes, there was a 34% reduction in ESRD risk

(p=0.02) (Figure 1). Few members without diabetes had 6 years of follow-up, and

cumulative incidence of ESRD was low among treated and controls (0.12% versus

0.11%; Table 2). We found no relationship between treatment persistence and risk of

ESRD in members without diabetes (Figure 2; Table 2).

End-Stage Liver Disease

GLP-1RA treatment was associated with lower ESLD risk in members with

and without diabetes (Figure 1). For members with diabetes, any GLP-1RA treatment

was associated with a 34% lower risk (p<0.001) of ESLD (Figure 1; Table 3). For

members with diabetes, the magnitude of the effect was similar for all three

components of the composite measure (Figure 1). In treated members without

diabetes there was a 24% reduction in ESLD, although the absolute differences in

ESLD incident rates were small, and only two of the component measures (liver

transplant, hepatic failure) were significantly lower in treated members (Figure 1;

Table 3).

The relationship between GLP-1RA persistence and reduced ESLD differed

by diabetes status. For members with diabetes, a sustained effect was found only in

members treated for ≥2 years (Figure 3; Table 3). For members without diabetes, we

found a sustained reduction in ESLD only in those treated between 1-2 years (Figure

3; Table 3). GLP-1RA treatment delayed the onset of ESLD among members with

diabetes: at 3 years, 0.48% of controls had developed ESLD, a threshold not reached

by members with any GLP-1RA treatment until an additional 8 months had elapsed.

The delay was significantly more pronounced with longer GLP-1RA treatment, with

long-term treated individuals taking an additional 2.3 years to reach this threshold.

Major Adverse Cardiac Events

GLP-1RA treatment was associated with a lower risk of MACE in members

with and without diabetes: relative risk was reduced by 10% and 8%, respectively

(Figure 1). Among members with diabetes, risks of three of the five component events

were reduced, the largest impact was on stroke and hospital admission for HF. Among

members without diabetes, stroke risk was reduced by 16%, the largest component-

specific effect (p<0.001).

MACE had the highest cumulative incidence of the three clinical outcome

measures. By 6 years, 6.7% of untreated members with diabetes and 2.2% of

members without diabetes had experienced a MACE (Figure 4; Table 4). Absolute

risk differences favored GLP-1RA therapy; detailed estimates are provided in Table 4.

Among members with diabetes, treatment for ≥2 years was associated with a

1.5 percentage-point absolute reduction in 6-year MACE incidence–the largest

absolute reduction observed across outcomes–and with delayed MACE onset. The

controls' 3-year cumulative MACE incidence of 3.3% was reached approximately 3

months later among those with any GLP-1RA exposure and 1.0 year later among

those treated for ≥2 years. Among members without diabetes, MACE rates did not

differ significantly after the 2nd year of follow-up regardless of treatment persistence.

Discussion

Our study is one of the largest published on the clinical impact of GLP-1RA use in actual practice. For members with diabetes, we find treatment with GLP-1RAs substantially decreases the risk of developing ESRD, ESLD or experiencing a MACE event. Members with diabetes are at much greater risk of developing ESRD, ESLD or experiencing a MACE event at baseline and this is reflected in the higher absolute reduction of these outcomes compared to members without diabetes. For members without diabetes, while the effects are more modest, we still find that treated members have lower rates of all three major outcomes. Our other major finding is that members with longer persistence are more likely to benefit. These results extend randomized-trial findings to unselected, working-age adults and quantify—for the first time in routine practice—the multi-year deferral of kidney, liver, and composite cardiovascular events.

Cardiovascular outcomes trials (including LEADER, SUSTAIN-6, and REWIND) have demonstrated that GLP-1RAs reduce the incidence of MACE and slow the progression of CKD. However, these trials enrolled highly selected patient populations and did not measure hard ESLD end points or time-to-event delays.[11-13] The 45% relative reduction in ESRD observed in our study aligns with the 45% decline in the renal composite reported for dulaglutide in REWIND, our accompanying finding of a 2.7-year delay in ESRD represents a new clinically meaningful finding. At the population level, treating 250 treatment-adherent patients for a year prevents one renal-failure case—an effectiveness comparable to statins for secondary prevention of MI.

Real-world data on ESLD have been sparse and heterogeneous; the present study demonstrates a 34% reduction in hazard and a 2.3-year delay in progression to

hepatic failure or transplant.[23] The attenuation of acute MI risk—non-significant

overall but reduced by 34% with long-term GLP-1RA exposure—mirrors trial-based

observations that coronary benefit may accrue more slowly than cerebrovascular or

heart-failure benefit, potentially reflecting differing pathophysiologic mechanisms and

persistence of exposure requirements.

Longer follow-up studies are recommended to evaluate the impact of GLP-

1RAs on people without diabetes. In this study, the follow-up time and smaller

absolute event rates in members without diabetes yielded wide confidence intervals

around HR estimates. For approximately every 235 patients with diabetes who stay

on a GLP-1RA for ≥12 months, one case of end-stage renal disease is averted within 6

years, and for liver failure the figure is approximately 270. Combined with the 2.7

year delay in dialysis and the 2.3 year delay in transplant-eligible ESLD, GLP1-RA

treatment could result in significant reductions in medical costs for these rare but

serious outcomes.[24,25]

This study has several limitations. Semaglutide was approved for diabetes in

2017 and in 2021 for obesity. Consequently, the number of treated individuals

without diabetes available for analysis was lower than those with diabetes. However,

this is still one of the largest studies to date of the impact of GLP-1RAs on people

without diabetes. While diabetes is consistently coded in claims data, obesity is not.[26]

Our decision to consider all members without diabetes as a single cohort should be

evaluated through comparing clinical data, such as electronic medical records, with

claims data. Finally, the study was limited to members receiving GLP-1RAs via

insurance benefits. Untreated members could have accessed GLP-1RAs via alternate

mechanisms such as compounding pharmacies. Any misclassification would

attenuate the observed differences between treated and untreated members.

We found that in members with diabetes persistent GLP-1RA therapy was

associated with a reduced incidence and delayed onset of kidney and liver failure, as

well as reduced rates of stroke and HF hospitalization. These findings provide real-

world evidence of both clinical benefit and potential economic value among select

patient population within a commercially insured cohort. Our study supports

guideline recommendations to prioritize GLP-1RAs for high-risk patients and

underscore the importance of adherence programs capable of supporting patients to

persist with therapy for ≥1 year.

Acknowledgements

Author Contributions: AM and CM had full access to all of the data in the study and

take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: HC, DW, AM, CM

Acquisition, analysis, or interpretation of data: HC, AM, CM, DW

Drafting of the manuscript: HC, AM, CM, LAT

Critical review of the manuscript for important intellectual content: HC, RH, JK,

VV, SH, LAT

Statistical analysis: AM, CM

Obtained funding: HC

Administrative, technical, or material support: RH, JK, VV, SH, LAT

Supervision: HC, DW

Conflict of Interest Disclosures: No benefits in any form have been or will be

received from a commercial party related directly or indirectly to the subject of this

manuscript. Dr. Hashmi reported receiving stock and options from Elevance Health.

Dr. Wennberg serves as a consultant to Blue Health Intelligence. No disclosures for

other authors.

Funding/Support: This study was funded by the Blue Cross Blue Shield Association.

Role of the Funder/Sponsor: The funder had a role in the collection of the data. The

funder had no role in the management of the data, conduct or design of the study,

analysis, or interpretation of the data. The funder had no role in the preparation of the

manuscript. The funder had a role in the review and approval of the manuscript. The

authors jointly agreed to submit the manuscript for publication.

AI Used in Manuscript Preparation: The drafting and refinement of this manuscript
were supported by OpenAI's ChatGPT, which assisted in enhancing the language and
clarity of the text.

Disclaimer: The content is solely the responsibility of the authors and does not
necessarily represent the official views of the funding entity.

Data Sharing Statement: Data will not be shared.

Additional Contributions: The authors acknowledge Bob Darin (concept, design,
review), Bolatito Adepoju (editing) and Thomas Parakilatu, Neha Jajodia, and Jen
Zhong (data management) for their valuable contributions to this project.

References

1. Hammond RA, Levine R. The economic impact of obesity in the United
States. Diabetes Metab Syndr Obes 2010;3:285-95. DOI:
10.2147/DMSOTT.S7384.

2. Adult Obesity Facts. Centers for Disease Control and Prevention.
(https://www.cdc.gov/obesity/php/data-research/adult-obesity-facts.html).

3. Association AD. Statistics About Diabetes. November 2, 2023
(https://diabetes.org/about-diabetes/statistics/about-diabetes).

4.   Global BMIMC, Di Angelantonio E, Bhupathiraju Sh N, et al. Body-mass

index and all-cause mortality: individual-participant-data meta-analysis of 239

prospective studies in four continents. Lancet 2016;388(10046):776-86. DOI:

10.1016/S0140-6736(16)30175-1.

5.   Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass

index with health care expenditures in the United States by age and sex. PLoS

One 2021;16(3):e0247307. DOI: 10.1371/journal.pone.0247307.

6.   Trogdon JG, Finkelstein EA, Hylands T, Dellea PS, Kamal-Bahl SJ. Indirect

costs of obesity: a review of the current literature. Obes Rev 2008;9(5):489-

500. DOI: 10.1111/j.1467-789X.2008.00472.x.

7.   Fisher M, Petrie MC, Ambery PD, Donaldson J, Ye J, McMurray JJ.

Cardiovascular safety of albiglutide in the Harmony programme: a meta-

analysis. Lancet Diabetes Endocrinol 2015;3(9):697-703. DOI:

10.1016/S2213-8587(15)00233-8.

8.   FDA. Declaratory Order: Resolution of Shortages of Semaglutide Injection

Products (Ozempic and Wegovy).

(https://www.fda.gov/media/185526/download).

9.   Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of

3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015;373(1):11-

22. (In eng). DOI: 10.1056/NEJMoa1411892.

10.   Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W.

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide

1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

Diabetologia 1993;36(8):741-4. (In eng). DOI: 10.1007/bf00401145.

11.   Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and

373   cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind,

374   randomised placebo-controlled trial. Lancet 2019;394(10193):121-130. DOI:

375   10.1016/S0140-6736(19)31149-3.

376   12.   Gilbert MP, Skelly J, Hernandez AF, et al. Effect of albiglutide on

377   cardiovascular outcomes in older adults: A post hoc analysis of a randomized

378   controlled trial. Diabetes Obes Metab 2024;26(5):1714-1722. DOI:

379   10.1111/dom.15479.

380   13.   Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and

381   cardiovascular outcomes with once-weekly subcutaneous semaglutide in the

382   treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes

383   Metab 2019;45(5):409-418. DOI: 10.1016/j.diabet.2018.12.001.

384   14.   Meurot C, Jacques C, Martin C, et al. Targeting the GLP-1/GLP-1R axis to

385   treat osteoarthritis: A new opportunity? J Orthop Translat 2022;32:121-129.

386   DOI: 10.1016/j.jot.2022.02.001.

387   15.   Krajnc N, Itariu B, Macher S, et al. Treatment with GLP-1 receptor agonists is

388   associated with significant weight loss and favorable headache outcomes in

389   idiopathic intracranial hypertension. J Headache Pain 2023;24(1):89. DOI:

390   10.1186/s10194-023-01631-z.

391   16.   Foley HE, Knight JC, Ploughman M, Asghari S, Audas R. Identifying cases of

392   chronic pain using health administrative data: A validation study. Can J Pain

393   2020;4(1):252-267. DOI: 10.1080/24740527.2020.1820857.

394   17.   Villumsen M, Schelde AB, Jimenez-Solem E, Jess T, Allin KH. GLP-1 based

395   therapies and disease course of inflammatory bowel disease.

396   EClinicalMedicine 2021;37:100979. DOI: 10.1016/j.eclinm.2021.100979.

397   18.   Harvey R, Drzayich Jankus D, Mosley D. Random assignment of proxy event

398   dates to unexposed individuals in observational studies: An automated

399   technique using SAS®. MWSUG 2012. Minneapolis, MN2012.

400   19.   RAND Bayesian Improved Surname Geocoding.

401   (https://www.rand.org/health-care/tools-methods/bisg.html).

402   20.   Wysham CH, Gauthier-Loiselle M, Bailey RA, et al. Development of risk

403   models for major adverse chronic renal outcomes among patients with type 2

404   diabetes mellitus using insurance claims: a retrospective observational study.

405   Current Medical Research and Opinion 2020;36(2):219-227. DOI:

406   10.1080/03007995.2019.1682981.

407   21.   Pan H-C, Chen J-Y, Chen H-Y, et al. GLP-1 receptor agonists' impact on

408   cardio-renal outcomes and mortality in T2D with acute kidney disease. Nature

409   Communications 2024;15(1):5912. DOI: 10.1038/s41467-024-50199-y.

410   22.   Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse

411   cardiovascular event definitions used in observational analysis of

412   administrative databases: a systematic review. BMC Med Res Methodol

413   2021;21(1):241. DOI: 10.1186/s12874-021-01440-5.

414   23.   Wester A, Shang Y, Toresson Grip E, Matthews AA, Hagström H. Glucagon-

415   like peptide-1 receptor agonists and risk of major adverse liver outcomes in

416   patients with chronic liver disease and type 2 diabetes. Gut 2024;73(5):835-

417   843. (In eng). DOI: 10.1136/gutjnl-2023-330962.

418   24.   USRDS. Healthcare Expenditures for Persons with ESRD. End-Stage Renal

419   Disease: Chapter 9. 2023. (https://usrds-adr.niddk.nih.gov/2023/end-stage-

420   renal-disease/9-healthcare-expenditures-for-persons-with-esrd).

25.   Ortner NH, Hanna. 2025 U.S. organ and tissue transplants: Estimated costs

and utilization, emerging issues, and solutions. 2025.

([https://www.milliman.com/en/insight/2025-us-organ-and-tissue-transplants-](https://www.milliman.com/en/insight/2025-us-organ-and-tissue-transplants-costs-utilization)

[costs-utilization](https://www.milliman.com/en/insight/2025-us-organ-and-tissue-transplants-costs-utilization)).

26.   Ammann EM, Kalsekar I, Yoo A, Johnston SS. Validation of body mass index

(BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes

recorded in US claims data. Pharmacoepidemiol Drug Saf 2018;27(10):1092-

1100. (In eng). DOI: 10.1002/pds.4617.

Table 1: Characteristics of Matched GLP-1RA Treated and Control Cohorts

Characteristic considered in the matching algorithm	Members with Diabetes			Members without Diabetes		
	Treated	Controls	SMD	Treated	Controls	SMD
	N = 413,404	N = 413,404		N = 329,420	N = 329,420	
Age at Index (Years), mean (SD)	52.4 (8.8)	52.5 (8.9)	0.01	46.7 (10.2)	46.7 (10.3)	0.01
Gender (% Female)	49.0%	49.0%	0	75.7%	75.7%	0
Race/Ethnicity						
White	63.5%	61.1%	0.05	70.5%	70.9%	0.01
Black	8.3%	8.8%	0.02	7.2%	7.2%	0
Hispanic	10.7%	11.7%	0.03	7.1%	7.1%	0
Other	4.6%	5.1%	0.02	2.9%	2.5%	0.02
Unknown	12.8%	13.3%	0.01	12.3%	12.3%	0
Type 1 Diabetes	2.0%	2.0%	0	0.0%	0.0%	0
Type 2 Diabetes with complications	34.3%	34.3%	0	0.0%	0.0%	0
Type 2 Diabetes without complications	63.7%	63.7%	0	0.0%	0.0%	0
Obesity	35.7%	35.7%	0	45.1%	45.1%	0
Liver Disease	4.2%	4.0%	0.01	2.7%	2.2%	0.01
Hypertension	61.8%	63.6%	0.04	35.4%	35.9%	0.01
Anxiety	11.7%	11.9%	0.01	20.1%	20.2%	0.00
Depression	9.4%	9.4%	0.00	14.0%	13.8%	0.01
Heart Failure	2.1%	2.1%	0.00	0.6%	0.3%	0.03
Coronary Artery Disease	6.9%	6.6%	0.01	2.1%	1.9%	0.01
Chronic Kidney Disease	4.2%	4.2%	0	0.9%	0.7%	0.02
Obstructive Sleep Apnea	11.0%	10.3%	0.02	9.7%	9.1%	0.02
Prior Treatment						
Insulin	13.6%	12.9%	0.02	0.0%	0.0%	0.00
SGLT2 Inhibitors	18.6%	16.2%	0.06	0.0%	0.0%	0.00
Sulfonylureas[a]	21.9%	21.3%	0.01	0.0%	0.0%	0.00
DPP-4 Inhibitors	10.5%	9.9%	0.02	0.0%	0.0%	0.00
Biguanides	72.4%	73.8%	0.03	2.3%	1.3%	0.08
Number of non-bariatric inpatient stays						
0	95.0%	95.2%	0.01	97.6%	97.8%	0.01
1	4.2%	3.9%	0.01	2.0%	1.9%	0.01
2+	0.9%	0.9%	0	0.3%	0.3%	0.01
Number of other prescription classes used at baseline						
0	5.2%	4.7%	0.02	4.5%	4.6%	0
1 to 3	30.4%	29.8%	0.01	25.0%	24.9%	0
4 to 6	29.3%	29.7%	0.01	28.0%	28.1%	0
7 to 9	17.9%	18.3%	0.01	20.1%	20.2%	0
10+	17.1%	17.5%	0.01	22.4%	22.3%	0

431 [a] The sulfonylureas category also includes meglitinide analogues and thiazolidinediones.

Table 2: 6-Year Cumulative Incidence and Hazard of End-Stage Renal Disease

Outcome	Degree of GLP-1 Persistence	Members with Diabetes					Members without Diabetes				
		Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]	Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]
End-Stage Renal Disease	**Controls**	0.94±0.10					0.11±0.05				
	Treated: Overall	**0.67±0.08**	**<0.001**	**0.55**	**0.49-0.61**	**<0.001**	0.12±0.06	0.807	0.66	0.46-0.94	0.021
	Treated: <1 year	0.92±0.13	0.809	0.82	0.70-0.96	0.012	0.12±0.08	0.831	0.62	0.4-0.96	0.031
	Treated: 1-<2 years	**0.57±0.18**	**<0.001**	**0.45**	**0.35-0.57**	**<0.001**	0.23±0.24	0.345	0.82	0.41-1.67	0.591
	Treated: >= 2 years	**0.46±0.11**	**<0.001**	**0.27**	**0.21-0.35**	**<0.001**	0.05±0.04	0.050	0.57	0.17-1.95	0.372
Kidney Transplant	**Controls**	0.12±0.03					0.03±0.02				
	Treated: Overall	0.11±0.03	0.660	**0.60**	**0.45-0.81**	**0.001**	0.03±0.02	1.000	0.60	0.35-1.03	0.064
	Treated: <1 year	0.13±0.05	0.716	0.65	0.43-0.97	0.036	0.03±0.03	1.000	0.46	0.22-0.94	0.032
	Treated: 1-<2 years	0.11±0.09	0.838	0.65	0.37-1.13	0.127	0.03±0.03	1.000	1.20	0.37-3.93	0.763
	Treated: >= 2 years	0.09±0.06	0.366	0.47	0.25-0.88	0.019	0.03±0.02	1.000	0.67	0.19-2.36	0.530
Dialysis	**Controls**	0.89±0.10					0.08±0.04				
	Treated: Overall	**0.63±0.07**	**<0.001**	**0.54**	**0.48-0.61**	**<0.001**	0.10±0.06	0.606	0.71	0.45-1.12	0.140
	Treated: <1 year	0.86±0.13	0.710	0.85	0.72-1.0	0.046	0.09±0.07	0.820	0.73	0.42-1.27	0.269
	Treated: 1-<2 years	0.57±0.19	0.003	**0.42**	**0.32-0.55**	**<0.001**	0.21±0.24	0.304	0.77	0.34-1.75	0.533
	Treated: >= 2 years	**0.44±0.11**	**<0.001**	**0.25**	**0.19-0.33**	**<0.001**	0.02±0.03	0.025	-	-	-

[a] Raw p-values for GLP-1 users overall were compared to a threshold of α=0.05. P-values by degree of GLP-1 persistence were compared to a Bonferroni-adjusted threshold of α=0.017 (0.05/3).

433 **Table 3: 6-Year Cumulative Incidence and Hazard of End-Stage Liver Disease**

Outcome	Degree of GLP-1 Persistence	Members with Diabetes					Members without Diabetes				
		Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]	Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]
End-Stage Liver Disease	**Controls**	1.08±0.11					0.26±0.07				
	Treated: Overall	**0.86±0.09**	**0.002**	**0.66**	**0.60-0.73**	**<0.001**	0.27±0.08	0.85	0.76	0.62-0.93	0.008
	Treated: <1 year	0.98±0.13	0.257	0.96	0.84-1.11	0.594	0.30±0.11	0.54	0.95	0.74-1.22	0.705
	Treated: 1-<2 years	1.01±0.28	0.649	**0.57**	**0.47-0.70**	**<0.001**	0.15±0.11	0.11	**0.43**	**0.28-0.66**	**<0.001**
	Treated: >= 2 years	**0.67±0.13**	**<0.001**	0.37	0.30-0.45	**<0.001**	0.26±0.15	1.00	0.68	0.35-1.31	0.253
Liver Cancer	**Controls**	0.17±0.04					0.05±0.05				
	Treated: Overall	0.20±0.04	0.306	0.71	0.56-0.89	0.003	0.02±0.02	0.23	0.93	0.54-1.58	0.786
	Treated: <1 year	0.24±0.08	0.103	1.17	0.84-1.64	0.348	0.03±0.03	0.45	1.64	0.85-3.19	0.143
	Treated: 1-<2 years	0.23±0.13	0.384	0.65	0.41-1.03	0.069	0.00±0.00	0.03	0.25	0.05-1.18	0.080
	Treated: >= 2 years	0.14±0.06	0.392	**0.30**	**0.18-0.50**	**<0.001**	0.01±0.02	0.11	0.17	0.02-1.38	0.097
Liver Transplant	**Controls**	0.09±0.04					0.02±0.03				
	Treated: Overall	0.06±0.02	0.176	0.61	0.41-0.89	0.011	0.02±0.01	1.00	0.43	0.21-0.91	0.028
	Treated: <1 year	0.07±0.03	0.434	0.89	0.51-1.54	0.675	0.02±0.02	1.00	0.50	0.20-1.24	0.134
	Treated: 1-<2 years	0.12±0.11	0.603	0.47	0.21-1.05	0.065	0.00±0.00	0.12	0.25	0.05-1.18	0.080
	Treated: >= 2 years	0.05±0.03	0.089	0.39	0.18-0.85	0.017	0.02±0.03	1.00	1.00	0.06-15.99	1.000
Hepatic Failure	**Controls**	0.93±0.10					0.24±0.07				
	Treated: Overall	0.73±0.08	**0.003**	**0.66**	**0.60-0.74**	**<0.001**	0.25±0.08	0.85	0.76	0.61-0.94	0.012
	Treated: <1 year	0.84±0.12	0.272	0.97	0.84-1.13	0.702	0.27±0.10	0.64	0.92	0.71-1.20	0.541
	Treated: 1-<2 years	0.83±0.25	0.475	**0.57**	**0.46-0.71**	**<0.001**	0.14±0.11	0.14	**0.42**	**0.27-0.68**	**<0.001**
	Treated: >= 2 years	0.59±0.12	**<0.001**	**0.36**	**0.28-0.45**	**<0.001**	0.25±0.15	0.90	0.81	0.39-1.69	0.578

434 [a] Raw p-values for GLP-1 users overall were compared to a threshold of α=0.05. P-values by degree of GLP-1 persistence were compared to a
435 Bonferroni-adjusted threshold of α=0.017 (0.05/3).

 Table 4: 6-Year Cumulative Incidence and Hazard of Major Adverse Cardiac Events

Outcome	Degree of GLP-1 Persistence	Members with Diabetes					Members without Diabetes				
		Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]	Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]
MACE	**Controls**	6.68±0.25					2.24±0.24				
	Treated: Overall	6.46±0.23	0.204	**0.90**	**0.86-0.93**	**<0.001**	2.49±0.25	0.152	0.92	0.86-0.99	0.019
	Treated: <1 year	**7.67±0.38**	**<0.001**	**1.17**	**1.12-1.23**	**<0.001**	2.57±0.30	0.094	1.04	0.95-1.14	0.390
	Treated: 1-<2 years	7.10±0.70	0.269	**0.77**	**0.71-0.82**	**<0.001**	2.40±0.58	0.615	**0.72**	**0.62-0.82**	**<0.001**
	Treated: >= 2 years	**5.09±0.30**	**<0.001**	**0.63**	**0.59-0.68**	**<0.001**	2.33±0.61	0.788	0.81	0.65-1.02	0.070
Acute MI	**Controls**	3.30±0.19					1.10±0.17				
	Treated: Overall	3.14±0.16	0.203	0.94	0.89-0.99	0.020	1.14±0.16	0.741	0.89	0.80-0.99	0.037
	Treated: <1 year	**3.73±0.27**	**0.010**	**1.29**	**1.19-1.39**	**<0.001**	1.23±0.21	0.352	0.96	0.84-1.09	0.503
	Treated: 1-<2 years	3.69±0.55	0.190	**0.77**	**0.70-0.86**	**<0.001**	0.96±0.37	0.505	0.77	0.63-0.95	0.013
	Treated: >= 2 years	**2.43±0.20**	**<0.001**	**0.66**	**0.60-0.73**	**<0.001**	0.96±0.33	0.459	0.86	0.61-1.21	0.385
Acute Coronary Syndrome	**Controls**	0.48±0.06					0.11±0.05				
	Treated: Overall	**0.60±0.07**	**0.011**	1.08	0.96-1.22	0.181	**0.20±0.07**	**0.037**	1.36	1.01-1.82	0.040
	Treated: <1 year	**0.71±0.12**	**0.001**	1.31	1.11-1.56	**0.002**	0.16±0.07	0.255	1.38	0.95-2.01	0.090
	Treated: 1-<2 years	0.59±0.21	0.326	0.85	0.67-1.09	0.196	0.18±0.14	0.349	1.18	0.67-2.09	0.564
	Treated: >= 2 years	0.52±0.09	0.472	0.96	0.76-1.21	0.727	0.33±0.27	0.113	1.67	0.73-3.81	0.226

437
438

    Table 4. Continued

Outcome	Degree of GLP-1 Persistence	Members with Diabetes					Members without Diabetes				
		Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]	Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]
Heart Failure	Controls	1.46±0.13					0.24±0.09				
	Treated: Overall	**1.15±0.10**	**<0.001**	**0.76**	**0.70-0.83**	**<0.001**	0.28±0.08	0.518	1.19	0.95-1.49	0.134
	Treated: <1 year	1.54±0.17	0.468	1.19	1.05-1.33	0.004	0.32±0.11	0.271	**1.64**	**1.22-2.20**	**0.001**
	Treated: 1-<2 years	1.27±0.27	0.214	**0.59**	**0.50-0.71**	**<0.001**	0.27±0.21	0.800	0.82	0.51-1.31	0.407
	Treated: >= 2 years	**0.72±0.13**	**<0.001**	**0.37**	**0.30-0.44**	**<0.001**	0.14±0.09	0.117	0.50	0.26-0.97	0.041
Stroke	Controls	2.48±0.15					0.91±0.15				
	Treated: Overall	2.43±0.15	0.645	**0.82**	**0.77-0.87**	**<0.001**	1.00±0.16	0.417	0.84	0.75-0.93	**0.001**
	Treated: <1 year	**2.92±0.25**	**0.004**	1.04	0.96-1.13	0.303	1.01±0.19	0.419	0.99	0.86-1.14	0.889
	Treated: 1-<2 years	2.52±0.43	0.863	**0.74**	**0.66-0.83**	**<0.001**	1.04±0.37	0.519	**0.60**	**0.49-0.75**	**<0.001**
	Treated: >= 2 years	**1.91±0.20**	**<0.001**	**0.58**	**0.51-0.65**	**<0.001**	0.97±0.45	0.804	0.68	0.48-0.98	0.039
Cardiac Revascularization	Controls	1.71±0.13					0.43±0.10				
	Treated: Overall	1.86±0.12	0.104	1.04	0.97-1.11	0.272	0.51±0.11	0.292	1.10	0.94-1.29	0.254
	Treated: <1 year	**2.10±0.20**	**0.001**	**1.35**	**1.22-1.49**	**<0.001**	0.50±0.12	0.393	1.14	0.94-1.40	0.186
	Treated: 1-<2 years	2.19±0.41	0.030	0.92	0.80-1.06	0.250	0.47±0.26	0.780	1.00	0.73-1.37	1.000
	Treated: >= 2 years	1.55±0.16	0.136	**0.75**	**0.65-0.85**	**<0.001**	0.63±0.31	0.234	1.06	0.65-1.74	0.803

440 [a] Raw p-values for GLP-1 users overall were compared to a threshold of α=0.05. P-values by degree of GLP-1 persistence were compared to a
441 Bonferroni-adjusted threshold of α=0.017 (0.05/3).

Fig 1. Hazard of Incident ESRD, ESLD, and MACE between GLP-1RA Treated and Controls, for Members with and without Diabetes.

🟩 GLP-1RA Treated at lower risk
🟧 GLP-1RA Treated at higher risk
⬜ No difference between GLP-1RA Treated and Controls

Members with Diabetes		Members without Diabetes	
Hazard Ratio for GLP-1RA Treated vs. Controls	HR, Cox p-value	Hazard Ratio for GLP-1RA Treated vs. Controls	HR, Cox p-value
ESRD	0.55, p < 0.001	ESRD	0.66, p = 0.02
Kidney Dialysis	0.54, p < 0.001	Kidney Dialysis	0.71, p = 0.14
Kidney Transplant	0.60, p < 0.001	Kidney Transplant	0.60, p = 0.06
ESLD	0.66, p < 0.001	ESLD	0.76, p = 0.008
Liver Cancer	0.71, p = 0.003	Liver Cancer	0.93, p = 0.79
Liver Transplant	0.61, p = 0.01	Liver Transplant	0.43, p = 0.03
Hepatic Failure	0.66, p < 0.001	Hepatic Failure	0.76, p = 0.01
MACE Composite	0.90, p < 0.001	MACE Composite	0.92, p = 0.02
AMI	0.94, p = 0.02	AMI	0.89, p = 0.04
ACS / UA Admits	1.08, p = 0.18	ACS / UA Admits	1.36, p = 0.04
HF Admits	0.76, p < 0.001	HF Admits	1.19, p = 0.13
Stroke	0.82, p < 0.001	Stroke	0.84, p < 0.001
Revascularization	1.04, p = 0.27	Revascularization	1.10, p = 0.25

Members with Diabetes x-axis: 0.4 0.6 0.8 1.0 1.2

Members without Diabetes x-axis: 0.4 0.8 1.2 1.6

Hazard ratios (HR) and p-values were generated by Cox proportional hazards models over the 6-year member follow-up period. Statistical significance was established using a threshold of α = 0.05.

Fig 2. Cumulative Incidence of ESRD by 3 Levels of GLP-1RA Persistence and Untreated Controls, for Members with and without Diabetes.

Log-rank p-value on the graphs shows that the cumulative incidence of ESRD varies by degree of persistence in members with diabetes but not significantly in members without diabetes. Tables below graphs show corresponding cumulative incidence rates (%) and 95% confidence bounds at one year timepoints. In the bottom table, raw p-values of Wald z-test comparisons between each GLP-1RA persistence stratum to the control group should be compared to a Bonferroni-adjusted threshold of α = 0.016 (0.05/3).

Fig 3. Cumulative Incidence of ESLD by 3 Levels of GLP-1RA Persistence and Untreated Controls, for Members with and without Diabetes.

Log-rank p-value on the graphs shows that the cumulative incidence of ESLD varies by degree of persistence in members with and without diabetes. Tables below graphs show corresponding cumulative incidence rates (%) and 95% confidence bounds at one year time timepoints. In the bottom table, raw p-values of Wald z-test comparisons between each GLP-1RA persistence stratum to the control group should be compared to a Bonferroni-adjusted threshold of α = 0.016 (0.05/3).

Fig 4. Cumulative Incidence of MACE by 3 Levels of GLP-1RA Persistence and Controls, for Members with and without Diabetes.

Log-rank p-value on the graphs shows that the cumulative incidence of MACE varies by degree of persistence in members with and without diabetes. Tables directly below graphs show corresponding cumulative incidence rates (%) and 95% confidence bounds at one year time intervals. Raw p-values of Wald z-test comparisons between each GLP-1RA persistence stratum to the control group should be compared to a Bonferroni-adjusted threshold of α = 0.016 (0.05/3).